????????, page-3

Yes it overvalued when compared to a biotech like Novogen which has much better downside protection and massive upside.

Still, once they start selling their product the risk profile will change. People are just getting in early.

I would buy them on a pull back to $4.50.

Looks like my $6 close target will get pretty close.